ACAD Acadia Pharmaceuticals Inc

$ACAD do your own dd but just saying in a diversified biotech portfolio I would add a reasonable amount of this at 19.80 or better. ~9pe. Less than 3x Rev to market cap. Around 25% of market cap is cash on hand. HELLO is this a bargain or am I crazy?

$ACAD we have patent protection far beyond the 7 year standard to me the alzheimers trial has a 70/30 to make it to market. It is also the replacement for nuplazid down the road. 35-40 could be a bid to buy the company

$ACAD Im one of the many bag holders here n I wish the Bakers would force a sale at this point. Beginning to think that it is time that they seriously consider packing it up n moving on. How long have they n others been here? It's been almost 11 yrs since Pima was approved n they were not able to get a single additional indication. They have continued to shoot in the dark in the hopes of hitting something n it is not getting them anywhere. This company desperately needs a sucessful trial. N by sucessful, I mean hit it out the park data.

$ACAD added more today in 19.30s up to 1% of my account definitely going to keep adding if this goes to the 17 or below range. Maybe I'm wrong but looks like free money.

$ACAD ⚠️10 Years ago this stock was $27, today it’s $19. ⚠️The Baker Brothers are BAKED steam piles. 👍🏼No thanks!

RBC Capital reiterated an Outperform rating and $37 price target on ACADIA Pharmaceuticals, arguing that the company’s established commercial franchise is trading at an unjustifiably large discount. RBC also said recent patent developments further reduce long-term revenue risk for Nuplazid. The call comes after ACAD shares were heavily oversold following the Sept. 24 announcement that experimental Alzheimer’s psychosis drug remlifanserin narrowly missed the primary endpoint in the Phase 2 RADIANT trial. The stock fell sharply again on Sept. 25 as several analysts cut price targets, while a securities litigation firm launched an investigation into the company’s communications surrounding the trial. Despite the setbacks, most analysts maintain Buy-equivalent ratings, with consensus targets implying substantial upside. A broader risk-on market, with the Nasdaq and S&P 500 higher, is also supporting beaten-down biotech stocks. $ACAD

$ACAD Get back to $30 you fool! Over a billion in revenue, sales of both drugs growing each quarter.

$ACAD options assigned with 240$ profit per contract but effectivelly buying shares at 24$.

$ACAD 2028 EPS ESTIMATE OF1.6 VERY VERY LOW PE FOR A DEEP PIPELINE 25 pt NEXT 6 MONTHS UPDATES ON TREMOR WILL MOVE HIGHER

$ACAD UBS Downgrades ACADIA Pharmaceuticals to Neutral From Buy, $23 Price Target 04:19 AM PDT, October 13, 2026

$ACAD If they don't give us any new news on this data in November, is this a $16 stock again?

$ACAD Where’s the bottom? A billion in revenue, two approved drugs, sales growth, a pipeline……🤮

$ACAD Last $20 buy sold yesterday over 20.5 and reloaded again today at $19.73. My 23$ core position intact 1